0001193125-26-220584
SEC filingClinical-stage biotech Upstream Bio reported strong revenue growth from partnerships offsetting deeper R&D-driven losses and higher cash burn, reflecting accelerated clinical investments while maintaining liquidity to fund operations through 2027.
Upstream Bio, Inc. (UPB) generated $1.0 million in Q1 FY2026 revenue, up 82.7% from $566 thousand in the prior-year quarter. This growth stems from collaboration reimbursements, notably from Maruho, which covers research and development costs including drug supply for key programs. As a clinical-stage biotech focused on respiratory diseases, this partnership revenue provides a modest but accelerating offset to operating expenses, signaling validation of the company's pipeline progress without reliance on product sales.
Net cash provided by operating activities was -$47.9 million, up from -$41.2 million YoY, as funds flow into R&D acceleration. Despite heightened burn, management affirms existing cash, cash equivalents, and short-term investments suffice to cover operating expenses and capital needs through 2027 under the current plan. This liquidity underpins advancement toward Phase 3 asthma and CRSwNP trials starting Q1 2027 and COPD data in H2 2027, positioning major catalysts ahead. Future business plan changes or expense growth from headcount and infrastructure could necessitate additional capital, but the current position aligns with strategic execution in this investment-heavy phase.